Beta-Alanine
PreclinicalSmall molecule
Beta-Alanine is one of 11 small molecule programs targeting Urinary incontinence. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Urinary Incontinence
#DrugCompanyPhaseTrials
1Vesicare
AstellasApproved
Myrbetriq
AstellasApproved
Cymbalta
Jazz PharmaceuticalsApproved
Enablex
AbbVieApproved
Toviaz
PfizerApproved
Alka-Seltzer
AAbbott
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Isopto Carpine
AAdvanz Pharma
Approved
Platelet Rich Plasma
ZZagazig University
Preclinical
Allogeneic Mesenchymal Stem Cells
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Beta-Alanine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital Olomouc